Halozyme Therapeutics, Inc.
HALOHalozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.
Drugs in Pipeline
10
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
Hylenex
Pain
Gemcitabine
Stage IV Pancreatic Cancer
Insulin aspart
Diabetes Mellitus, Type II
Mitomycin C
Bladder Cancer
Humalog
Type 1 Diabetes Mellitus
PEGPH20
Metastatic Pancreatic Cancer
rHuPH20
Dermatitis, Allergic Contact
regular human insulin
Diabetes Mellitus, Type 1
Humulin-R
Diabetes Mellitus, Type 2
Insulin lispro
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Hylenex | Phase 3 | Pain | - | - |
Gemcitabine | Phase 2 | Stage IV Pancreatic Cancer | - | - |
Insulin aspart | Phase 2 | Diabetes Mellitus, Type II | - | - |
Mitomycin C | Phase 2 | Bladder Cancer | - | - |
Humalog | Phase 2 | Type 1 Diabetes Mellitus | - | - |
PEGPH20 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
rHuPH20 | Phase 2 | Dermatitis, Allergic Contact | - | - |
regular human insulin | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Humulin-R | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Insulin lispro | Phase 2 | Diabetes Mellitus, Type 1 | - | - |